Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:35:33 EDT Tue 07 May 2024
Enter Symbol
or Name
USA
CA



News for U:COCP from 2023-05-08 to 2024-05-07 - 17 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-01 08:00U:COCPNews ReleaseEnrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
2024-03-28 08:00U:COCPNews ReleaseCocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
2024-03-19 08:00U:COCPNews ReleaseCocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
2024-03-05 08:34U:COCPNews ReleaseCocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
2024-01-04 08:00U:COCPNews ReleaseCocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
2023-12-06 08:00U:COCPNews ReleaseCocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
2023-11-29 08:00U:COCPNews ReleaseCocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
2023-11-27 08:00U:COCPNews ReleaseCocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
2023-11-13 08:00U:COCPNews ReleaseCocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
2023-11-09 08:00U:COCPNews ReleaseCocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
2023-10-31 08:00U:COCPNews ReleaseCocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
2023-09-28 08:00U:COCPNews ReleaseCocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus
2023-09-05 08:00U:COCPNews ReleaseCocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
2023-08-14 08:00U:COCPNews ReleaseCocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
2023-08-08 08:00U:COCPNews ReleaseCocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
2023-05-31 08:00U:COCPNews ReleaseCocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988
2023-05-15 08:00U:COCPNews ReleaseCocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs